Different genes are potentially activated in lean and adipose tissue in response to recombinant human growth hormone (GH) or its mediator, insulin-like growth factor 1. Decker and colleagues now present evidence that levels of circulating protein markers give clues about the biological efficacy of GH therapy in various body tissue compartments.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Decker, R. et al. Protein markers predict body composition during growth hormone (GH) treatment in short prepubertal children. Clin. Endocrinol. (Oxf.) http://dx.doi.org/10.1111/cen.12196.
Andersson, B., Hellgren, A., Nierop, A. F., Hochberg, Z. & Albertsson-Wikland, K. Proteins related to lipoprotein profile were identified using a pharmaco-proteomic approach as markers for growth response to growth hormone (GH) treatment in short prepubertal children. Proteome Sci. 7, 40 (2009).
Shen, W., St-Onge, M.-P., Wang, Z. & Heymsfield, S. B. in Human Body Composition 2nd edn (eds Heymsfield, S. B., Lohman, T. G., Wang, Z. & Going, S. B.) 3–14 (Human Kinetics, Champaign, IL, 2005).
Gaillard, R. C. et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur. J. Endocrinol. 166, 1069–1077 (2012).
Gibney, J. et al. The effects of 10 years recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 84, 2596–2602 (1999).
Elbornnsson, M. et al. Fifteen years of growth hormone (GH) replacement improves body composition and cardiovascular risk factors. Eur. J. Endocrinol. http://dx.doi.org/10.1530/EJE-12-1083.
Roemmich, J. N., Huerta, M. G., Sundaresan, S. M. & Rogol, A. D. Alterations in body composition and fat distribution in growth hormone-deficient prepubertal children during growth hormone therapy. Metabolism 50, 537–547 (2001).
Sanchez-Ortega, R., Klibanski, A. & Tritos, N. A. Effects of recombinant human growth hormone in adults with Prader-Willi syndrome: a meta-analysis. Clin. Endocrinol. (Oxf.) 77, 86–93 (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares that he has consulted for AbbVie and SOV Therapeutics.
Rights and permissions
About this article
Cite this article
Rogol, A. Biological markers of tissue-specific effects of GH therapy. Nat Rev Endocrinol 9, 318–320 (2013). https://doi.org/10.1038/nrendo.2013.80
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.80
